



**IBEX TECHNOLOGIES INC.**

**MANAGEMENT DISCUSSION AND ANALYSIS**

**FISCAL 2022**

**SIX MONTHS ENDED  
JANUARY 31, 2022**

**As at March 16, 2022**



---

**MANAGEMENT DISCUSSION AND ANALYSIS  
FOR THE SIX MONTHS ENDED JANUARY 31, 2022  
March 16, 2022  
TABLE OF CONTENTS**

1. PREAMBLE
2. FORWARD-LOOKING STATEMENTS
3. INTRODUCTION TO IBEX
  - 3.1. Enzymes
  - 3.2. Arthritis Assays
4. RESULTS OF OPERATIONS: Q2 FISCAL 2022
  - 4.1. Summary of Quarterly Results
  - 4.2. Foreign Exchange
  - 4.3. Revenues for the Quarter
  - 4.4. Total expenses for the Quarter
    - 4.4.1. Cost of Sales
    - 4.4.2. Research and Development Expenses
    - 4.4.3. Selling, General and Administrative Expenses
5. RESULTS OF OPERATIONS: SIX MONTHS ENDED JANUARY 31, 2022
  - 5.1. Summary of Results
  - 5.2. Foreign Exchange
  - 5.3. Revenues
  - 5.4. Total Expenses
    - 5.4.1. Cost of Sales
    - 5.4.2. Research and Development Expenses
    - 5.4.3. Selling, General and Administrative Expenses
6. LIQUIDITY AND CAPITAL RESOURCES
7. LOOKING FORWARD
8. RISKS AND UNCERTAINTIES
9. RELATED PARTY TRANSACTIONS
10. CRITICAL ACCOUNTING ESTIMATES
11. ACCOUNTING STANDARDS AND AMENDMENTS
12. OUTSTANDING SHARE DATA
  - 12.1. Common Shares
  - 12.2. Stock Options
13. COVID-19 IMPACT



---

## MANAGEMENT DISCUSSION AND ANALYSIS

March 16, 2022

### 1 PREAMBLE

The following Management Discussion and Analysis (“MD&A”) and the unaudited condensed interim consolidated financial statements (“interim financial statements”) of IBEX Technologies Inc. (the “Company”) were approved by the Audit Committee and the Board of Directors on March 16, 2022. This MD&A provides a review of the developments and results of operations of the Company during the second quarter ended January 31, 2022 compared with the second quarter ended January 31, 2021.

This MD&A should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the years ended July 31, 2021 and 2020

The Company’s interim financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). Additional information relating to the Company, including the Company’s Proxy Circular, can be found on SEDAR at [www.sedar.com](http://www.sedar.com).

Where “IBEX” or “the Company” is used, it refers to IBEX Technologies Inc. and its’ wholly owned subsidiaries, unless otherwise indicated. All amounts are in Canadian dollars, unless otherwise indicated.

### 2 FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements that reflect the Company’s current expectations regarding future events. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. For more information on the Company’s risks and uncertainties relating to these forward-looking statements, please refer to the risks and uncertainties section of the MD&A.

### 3 INTRODUCTION TO IBEX

#### 3.1 Enzymes

The Company, through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use.

The Company’s products are sold directly by the Company to manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers and academic research institutions.

Heparinase I is the most important of the IBEX enzymes. Its potential lies in its ability to cleave heparin and low molecular weight heparins and thereby neutralize the effects of heparin and heparinoids, which are drugs commonly used in hospitals and which interfere with hemostasis tests. Heparinase I recognizes and cleaves a pentasaccharide sequence which occurs in both unfractionated heparin and the low molecular weight heparins, thereby neutralizing their anticoagulant activity and thus facilitating the accurate measurement of hemostasis.



IBEX heparinase I is made via a proprietary process and is the only heparinase I approved for use in clinical diagnostics in North America and Europe.

In addition to making and selling enzymes, IBEX also provides lyophilization services for the making of disposable medical diagnostic device components used in the hemostasis point-of-care market

### 3.2 Arthritis Assays

IBEX develops, manufactures and sells arthritis assay kits which enable the study of both the synthesis and degradation of cartilage components. These assays are powerful tools in the study of osteo and rheumatoid arthritis. These assays are a result of both internal research and development, and the in-licensing of technology from academic research institutions.

IBEX arthritis diagnostic kits and services are marketed and sold for research use only (“RUO”) to pharmaceutical companies, clinical research organizations and academic institutions. These diagnostic kits are marketed through distributors in Europe and Japan, and directly by IBEX in North America and the rest of the world. The kits are produced in IBEX facilities.

## 4 RESULTS OF OPERATIONS: Q2 FISCAL 2022

### 4.1 Summary of Quarterly Results

The following table is a summary of selected quarterly consolidated financial information of the Company for each of the eight most recently completed quarters.

(in thousands of dollars, excluding per share amounts)	Q2		Q1		Q4		Q3		12 Mos Ending Jan 31	
	F2022 \$	F2021 \$	F2022 \$	F2021 \$	F2021 \$	F2020 \$	F2021 \$	F2020 \$	2022 \$	2021 \$
- Revenues	1,832	1,313	1,781	1,165	1,361	1,447	1,468	1,679	6,442	5,604
- Net earnings	405	249	665	150	29	304	334	626	1,433	1,329
- Earnings per common share	0.02	0.01	0.03	0.01	-	0.01	0.01	0.02	0.06	0.05
- Comprehensive income	405	249	665	150	29	316	334	613	1,433	1,328
- EBITDA	496	348	763	246	343	230	432	769	2,034	1,593

### Net Earnings for the Quarter

The Company recorded net earnings of \$405,469 during the second quarter ended January 31, 2022, an increase of \$156,964 (63%) compared to prior year. The positive change is explained by an increase in revenues of \$519,123 (see section 4.3), partially offset by an increase in net expenses of \$362,159 (see section 4.4).

The above led the Company to record an EBITDA for the quarter of \$495,783 versus \$347,891 last year, an increase of \$147,892.

*It should be noted that Earnings Before Interest, Tax, Depreciation & Amortization (“EBITDA”) is not a performance measure defined by IFRS, but we, as well as investors and analysts, consider that this performance measure facilitates the evaluation of our ongoing operations and our ability to generate cash flows to fund our cash requirements, including our capital expenditures program. Note that our definition of this measure may differ from the ones used by other public corporations. The elements include in the Company’s EBITDA are: Net earnings (loss), Depreciation of property, plant, equipment and intangible assets, Depreciation of right-of-use assets, Interest-Net, Income tax expense (recovery).*

## 4.2 Foreign Exchange

The tables below show the fluctuation in the Canadian/US dollar exchange rates which can have a significant impact on the Company’s results. Average rates are used to translate revenues and expenses for the period mentioned; closing rates are used to translate assets and liabilities of foreign operations, as well as monetary assets and liabilities at the end of the reporting period.

Consolidated foreign exchange loss (gain)		
Quarter ended	January 31, 2022	January 31, 2021
Balance sheet revaluation		
• US cash	<b>(\$38,223)</b>	\$96,811
• US Trade receivables	<b>(\$18,197)</b>	\$5,347
• Other US accounts	<b>(\$3,546)</b>	\$11,305
Total loss / (gain) on revaluation	<b>(\$59,966)</b>	\$113,463

Canadian/US dollar		
Quarter ended	January 31, 2022	January 31, 2021
Average rate	<b>1.2660</b>	1.2867
Closing rate	<b>1.2719</b>	1.2780

## 4.3 Revenues for the Quarter

*Note: While the Company reports in Canadian dollars, the US dollar is the Company’s selling currency. As such, fluctuations in the Canadian/US dollar exchange rate can have a significant impact on the reported revenue figures.*

Revenues for the quarter ended January 31, 2022 totaled \$1,832,038, an increase of \$519,123 (40%) compared to the same period year ago, due to a combination of COVID driven increases in the use of heparinase I, and changes in quarterly purchasing patterns on the part of several of our major customers.

Revenues comprise both actual sales and the effect of currency changes. The increase in revenues is due to an increase in volume of \$768,147 (US\$606,751) offset by a decrease in product mix of \$221,875 (US\$175,256) and a negative currency impact of \$27,149.

Revenues Variations – Quarter ended	January 31, 2022 vs. January 31, 2021
Volume/mix/new products impact:	
• Increase due to volume USD	606,751
• Decrease due to product mix USD	(175,256)
Total increase due to volume/mix USD	431,495
Currency impact:	
• Total increase due to volume/mix CAD	546,272
• Currency negative effects in CAD	(27,149)
• Total increase in CAD	519,123

#### 4.4 Total Expenses for the Quarter

Total expenses before taxes for the second quarter of fiscal 2022 increased by \$362,212 to \$1,426,569 compared to \$1,064,357 in the same quarter year ago.

Expense details		
Quarter ended	January 31, 2022	January 31, 2021
Cost of sales <sup>1</sup>	<b>541,852</b>	\$555,686
R&D expenses <sup>1</sup>	<b>65,682</b>	\$15,147
SG&A expenses <sup>1</sup>	<b>783,172</b>	\$435,635
Depreciation of PPE <sup>2</sup>	<b>35,932</b>	\$42,638
Depreciation of right-of-use assets	<b>52,746</b>	\$51,100
Foreign exchange loss/ (gain)	<b>(59,966)</b>	\$113,463
Financial expenses - net	<b>7,151</b>	\$10,394
Total expenses before other gains	<b>1,426,569</b>	\$1,224,063
Other income (CEWS)	-	(\$159,706)
Total expenses	<b>1,426,569</b>	\$1,064,357

1- Excludes related depreciation expense for the purposes of this presentation.

2- PPE = Property, plant and equipment and intangible assets.

#### 4.4.1 Cost of Sales

The Company uses the actual-cost method of recording its production costs rather than a standard-cost method (because of the practicalities of the Company's production, the standard-cost method is unsuitable). While the actual-cost method is most suitable to the Company's processes, it does result in wide swings from quarter to quarter in the cost of sales due to the "inventory allocation" effect (if more goods are produced in a quarter than are sold, there is a positive effect on the results; the reverse is true if more goods are sold than are produced).

Cost of sales consists principally of the cost of supplies, royalties, manufacturing labour and the allocation of fixed overheads.

Cost of sales		
Quarter ended	January 31, 2022	January 31, 2021
Revenues	1,832,038	\$1,312,915
Cost of sales <sup>3</sup>	573,204	\$610,376
Gross margin %	69%	54%

3- Includes related depreciation expense for the purposes of this presentation.

The increase in gross margin is due to cost allocation (the level of transfer of salaries, supplies, royalties and overheads to inventory) rather than to a decrease in the costs of materials or labour.

#### 4.4.2 Research and Development Expenses

Research and development (R&D) expenses consisted primarily of personnel expenses, laboratory supplies and external service providers. During the quarter ended January 31, 2022, research and development expenses totaled \$65,682 compared to \$15,147 in the same period year ago mainly due to the development of diamine oxidase (DiaMaze<sup>®</sup>), an enzyme being developed for the nutraceutical market.

#### 4.4.3 Selling, General and Administrative Expenses

During the quarter ended January 31, 2022, selling, general and administrative (SG&A) expenses totaled \$783,172, an increase of \$347,537 from the same period year ago. The increase is mainly due to the recording of a profit sharing program accrual as well as an increase in stock options expense this quarter due to the vesting of options in January for shares granted in December.

### 5 RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JANUARY 31, 2022

#### 5.1 Summary of Results

The Company recorded net earnings of \$1,070,029 for the six months ended January 31, 2022 compared to a net earnings of \$398,571 for the same period year ago. This increase of \$671,458 is primarily attributable to higher revenues of \$1,135,666 (see section 5.4), partially offset by an increase in net expenses of \$464,208 (see section 5.3).

This resulted in an EBIDTA of \$1,258,994, an increase of \$664,673 versus last year.

Net earnings		
Year-to-date	Fiscal 2022	Fiscal 2021
Revenues	\$3,613,239	\$2,477,573
Net expenses	\$2,543,210	\$2,079,002
Net earnings	\$1,070,029	\$398,571
Earnings per share, basic and diluted	0.04	0.02

## 5.2 Foreign Exchange

The table below shows the fluctuation in the Canadian/US exchange rates which can have a significant impact on the Company's results. As mentioned in section 4.2, average rates are used to translate revenues and expenses for the period mentioned; closing rates are used to translate assets and liabilities of foreign operations, as well as monetary assets and liabilities at the end of the reporting period.

Consolidated cumulative foreign exchange loss / (gain)		
Year-to-date	Fiscal 2022	Fiscal 2021
Balance sheet revaluation		
• US Cash	(\$18,569)	\$100,130
• US Trade receivables	\$15,512	(\$12,894)
• Other US accounts	(\$35,287)	\$31,154
Total loss / (gain) on revaluation	(\$38,344)	\$118,390

Canadian/US dollar rates		
Year-to-date	January 31, 2022	January 31, 2021
Average rate	1.2615	1.3044
Closing rate	1.2719	1.2780

## 5.3 Revenues

Revenues for the six months ended January 31, 2021 totaled \$3,613,239, an increase of \$1,135,666 due to a combination of COVID driven increases in the use of heparinase I, and changes in quarterly purchasing patterns on the part of several of our major customers.

The positive variance can be attributed to a volume increase of \$1,472,041 (US\$1,166,882) offset by a decrease in product mix of \$249,630 (US\$197,880), and a negative currency effect of \$86,745.

Revenues Variations – Year-to-date	Fiscal 2022 vs. Fiscal 2021
Volume/mix/new products impact:	
• Increase due to volume USD	1,166,882
• Increase due to product mix USD	(197,880)
Total increase due to volume/mix USD	969,002
Currency impact:	
• Total increase due to volume/mix CAD	1,222,411
• Currency negative effects CAD	(86,745)
• Total increase in CAD	1,135,666

## 5.4 Total Expenses

Total expenses before taxes for the six months ended January 31, 2022 increased by \$460,255 to \$2,543,210 compared to \$2,082,955 for the same period a year ago.

Expense details		
Year-to-date	Fiscal 2022	Fiscal 2021
Cost of sales <sup>4</sup>	<b>\$1,161,706</b>	\$1,038,220
R&D expenses <sup>4</sup>	<b>\$122,780</b>	\$22,365
SG&A expenses <sup>4</sup>	<b>\$1,096,544</b>	\$902,242
Depreciation of PPE	<b>\$79,313</b>	\$92,606
Depreciation of right-of-use assets	<b>\$105,039</b>	\$97,028
Foreign exchange loss / (gain)	<b>(38,344)</b>	\$118,390
Financial expenses - net	<b>16,172</b>	\$19,978
Total expenses before other gains	<b>\$2,543,210</b>	\$2,290,829
Other income (CEWS)	-	(\$207,874)
Total expenses	<b>\$2,543,210</b>	\$2,082,955

4- Excludes related depreciation expense for the purposes of this presentation.

### 5.4.1 Cost of Sales

Cost of Sales consists principally of the costs of supplies, royalties, manufacturing labour and the allocation of fixed overheads. For further explanation on the determination of the cost of sales, see section 4.4.1 above.

Cost of sales		
Year-to-date	Fiscal 2022	Fiscal 2021
Revenues	<b>\$3,613,239</b>	\$2,477,573
Cost of sales <sup>5</sup>	<b>\$1,230,632</b>	\$1,142,976
Gross margin %	<b>66%</b>	54%

5- Includes related depreciation expense for the purposes of this presentation.

The increase in gross margin is due to cost allocation (the level of transfer of salaries, supplies, royalties and overheads to inventory) rather than to a decrease in the costs of materials or labour.

#### 5.4.2 Research and Development Expenses

Research and development (R&D) expenses for the six months ended January 31, 2022 totaled \$122,780 compared to \$22,365 for the same period year ago. The \$100,415 increase is due to the development of diamine oxidase (DiaMaze<sup>®</sup>), an enzyme being developed for the nutraceutical market.

#### 5.4.3 Selling, General and Administrative Expenses

Selling, general and administrative (SG&A) expenses for the six months ended January 31, 2022 totaled \$1,096,544 compared to \$902,242 for the same period year ago. The variance of \$194,302 is mainly due to a bonus accrual as well as stock options expense recorded this quarter offset by a decrease in salaries and consultants.

## 6 LIQUIDITY AND CAPITAL RESOURCES

Liquidity risk is the potential risk that the Company will not be able to meet its financial liabilities when due. The Company's financial liabilities include its accounts payable and accrued liabilities presented on the consolidated statement of financial position, which are due within the next 12 months. The Company manages liquidity risk by maintaining adequate cash balances to discharge its liabilities when due.

As at January 31, 2022, the Company had net working capital of \$5,942,847 compared to net working capital of \$4,731,334 as at July 31, 2021. Cash and cash equivalents increased by \$1,001,074 since the last quarter to \$6,209,764.

As at:	January 31, 2022	October 31, 2021	July 31, 2021	April 30, 2021	January 31, 2021
Cash and cash equivalents	<b>\$6,209,764</b>	\$5,208,690	\$4,433,901	\$4,210,710	\$3,851,406
Net working capital	<b>\$5,942,847</b>	\$5,357,827	\$4,731,334	\$4,560,820	\$4,275,151

Management believes that the Company has sufficient funds to meet its obligations and planned expenditures for the ensuing twelve months as they fall due. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period.

## **7 LOOKING FORWARD**

As always, the future financial results of the Company are difficult to predict as the Company's customers have significant variations in their purchasing patterns, as it has been illustrated in the quarterly results over the past few years. The impact of COVID-19 adds further uncertainty as it is possible that some of our customers have increased their inventories over supply-chain concerns

The Company continues to support a number of our customers who are developing of new clinical devices which contain an IBEX enzyme. Some of these may result in additional revenues in calendar 2022. However, as with all developmental projects, we cannot give assurances that any of these customer-driven projects will come to market and produce significant revenues.

We are continuing with our development of the enzyme DiaMaze® (diamine oxidase). DiaMaze® is an enzyme targeted to persons suffering from histamine intolerance and will be marketed as a nutraceutical. While we continue to make good progress, development of this product relies on a number of third-party suppliers whose deliverables have been slower than expected, due to COVID-19 constraints.

## **8 RISKS AND UNCERTAINTIES**

The results of operations and financial condition of the Company are subject to a number of risks and uncertainties and are affected by a number of factors outside the control of Management.

For more information, and for a complete description of the risk factors that could materially affect the business, please refer to the corresponding sections in the Company's July 31, 2021 MD&A, as they are the same for the six months ended January 31, 2022.

## **9 RELATED PARTY TRANSACTIONS**

During the six months ended January 31, 2022 and 2021, other than the transactions and amounts described in *Note 9* in our interim financial statements, the Company did not have any other related party transactions.

## **10 CRITICAL ACCOUNTING ESTIMATES**

Please refer to *Note 2* of the Company's July 31, 2021 audited consolidated financial statements and the corresponding section of the July 31, 2021 MD&A to review the Company's critical accounting

estimates. They were the same as those used in the interim financial statements for the six months ended January 31, 2022.

## **11 ACCOUNTING STANDARDS AND AMENDMENTS**

Please refer to *Note 2* of the Company's January 31, 2022 interim financial statements.

New accounting standards, amendments and interpretations issued and effective for the Company beginning on August 1, 2020 are as follows:

*IAS 1, Presentation of Financial Statements ("IAS 1"), and IAS 8, Accounting Policies, Changes in accounting Estimates and Errors ("IAS 8")*

Definition of Material (Amendments to IAS 1, Presentation of Financial Statements, and to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors) is intended to make the definition of material in IAS 1 easier to understand and is not intended to alter the underlying concept of materiality in IFRS Standards. The concept of "obscuring" material information with immaterial information has been included as part of the new definition. The threshold for materiality influencing users has been changed from "could influence" to "could reasonably be expected to influence". The definition of material in IAS 8 has been replaced by a reference to the definition of material in IAS 1.

IAS 1 and IAS 8 are applicable for annual periods beginning on or after January 1, 2020. The Company does not expect any impact in its financial statements upon the amendments of IAS 1 and IAS 8.

## **12 OUTSTANDING SHARE DATA**

### **12.1 Common Shares**

As at March 16, 2022, the Company has 24,823,244 common shares outstanding.

### **12.2 Stock options**

As at March 16, 2022, the Company has 1,615,000 stock options outstanding with exercise prices ranging from \$0.14 to \$0.48 and expiry dates ranging from April 2027 to December 2031.

As at March 16, 2022, on an if-converted basis, these stock options would result in the issuance of 1,615,000 additional common shares at an aggregate exercise price of \$407,400.

## **13 COVID-19 IMPACT**

As an "Essential Service" (producing reagents and components for critical care diagnostic tests), IBEX has remained operational throughout the COVID-19 pandemic. To the extent possible,

administrative staff work mainly from home and production and lab staff are on site on an as-needed basis. COVID-19 has thus far not impacted our ability to produce and sell.

As noted above, our financial picture has actually improved, as customers have increased their purchases of our products (which mainly end up in diagnostics used in hospitals), however like many companies in the medical environment we do not have a clear picture of how COVID-19 will impact future sales.

The COVID-19 situation has however had an impact on some of our developmental programs, which rely heavily on external suppliers, some of which have been closed down as a result of the pandemic. Some of these programs have resumed in the past months as suppliers resumed operations

\* \* \* \* \*